The landscape of Alzheimer’s disease (AD) diagnosis and treatment is undergoing a significant transformation thanks to the groundbreaking Simoa® technology by Quanterix. This ultra-sensitive immunoassay platform is reshaping how biomarkers are identified and validated, offering new possibilities
The quest for faster and more efficient protein structure prediction has taken a significant leap forward with the advent of MassiveFold, a new iteration of AlphaFold designed for parallel processing. Within the realm of molecular biology and drug discovery, the speed and accuracy of protein
A new partnership between two powerhouses in the pharmaceutical industry promises substantial advancements in drug discovery and development. Novartis, one of the largest pharmaceutical companies globally, will pay Schrödinger $150 million upfront to utilize its advanced computing tools and
Insilico Medicine, an AI-based drug developer, has made significant strides with its lead candidate, ISM001-055, in the treatment of idiopathic pulmonary fibrosis (IPF). Following promising results from a Phase IIa trial, the company is now gearing up for potentially pivotal clinical trials that
Imagine a common over-the-counter pain reliever having the potential to alleviate the symptoms of a rare genetic disorder that currently lacks any formal treatment. This possibility could mark a significant breakthrough for patients who face enormous challenges and discomfort due to their
The recent approval of Aucatzyl by the FDA marks a significant advancement in the treatment landscape for patients with B-cell precursor acute lymphoblastic leukemia, especially those whose disease has progressed following initial chemotherapy treatments. Developed by U.K.-based Autolus
